Trastuzumab Recruiting Phase 2 Trials for Progesterone Receptor Negative / Triple-Negative Breast Cancer (TNBC) / Progesterone Receptor-negative Breast Cancer / Estrogen Receptor Positive / Stage IIA Breast Cancer / Triple-Negative Breast Carcinoma / Her2-Positive Breast Cancer / Progesterone Receptor Positive / HER2/Neu Positive / Estrogen Receptor-negative Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer / HER2/Neu Negative / Progesterone Receptor-positive Breast Cancer / Invasive Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIA Breast Cancer / Estrogen Receptor Negative / Stage IIB Breast Cancer / Stage IIIC Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT03125928Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03094052Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy